Oral contraceptives and venous thromboembolism: Consensus opinion from an international workshop held in Berlin, Germany in December 2009

Journal of Family Planning and Reproductive Health Care

Volumn 36, Issue 3, 2010, Pages 117-122

  Reid, Robert L ^a   Westhoff, Carolyn ^b   Mansour, Diana ^c   De Vries, Corrine ^d   Verhaeghe, Johan ^e   Boschitsch, Ewald ^f   Gompel, Anne ^g   Birkhäuser, Martin ^h   Křepelka, Petr ⁱ   Duliček, Petr ^j   Iversen, Ole Erik ^k   Khamoshina, Marina ^l   Dežman, Lucija Vrabič ^m   Fruzzetti, Franca ⁿ   Szarewski, Anne ^o   Wilken Jensen, Charlotte ^p   Seidman, Daniel ^q   Kaaja, Risto ^r   Shapiro, Samuel ^s  

^a QUEEN S UNIVERSITY   (Canada)

^b New York Presbyterian Columbia University Medical Center   (United States)

^c New Croft Centre   (United Kingdom)

^d University of Bath   (United Kingdom)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f Ambulatorium Klimax   (Austria)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ INSTITUTE FOR THE CARE OF MOTHER AND CHILD   (Czech Republic)

^j University Hospital   (Czech Republic)

^k UNIVERSITY OF BERGEN   (Norway)

^l PEOPLES FRIENDSHIP UNIVERSITY OF RUSSIA   (Russian Federation)

^m Health Centre Kranj   (Slovenia)

ⁿ SANTA CHIARA HOSPITAL   (Italy)

^o QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^p ROSKILDE HOSPITAL   (Denmark)

^q TEL AVIV UNIVERSITY   (Israel)

^r UNIVERSITY OF TURKU   (Finland)

^s UNIVERSITY OF CAPE TOWN   (South Africa)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; CERULOPLASMIN; DESOGESTREL; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTROGEN; GESTAGEN; GESTODENE; INGENIX; LEVONORGESTREL; LIVER PROTEIN; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY; SEX HORMONE BINDING GLOBULIN; TRANSCORTIN; UNCLASSIFIED DRUG; PROGESTERONE;

ABORTION; ACNE; AWARENESS; BODY MASS; BREAKTHROUGH BLEEDING; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DELIVERY; DEMOGRAPHY; DISEASE MARKER; DISEASE REGISTRY; DOPPLER FLOWMETRY; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSMENORRHEA; ENDOMETRIUM CANCER; FAMILY HISTORY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HAZARD RATIO; HEREDITY; HIRSUTISM; HORMONAL CONTRACEPTION; HORMONAL THERAPY; HUMAN; IMMOBILIZATION; LAW SUIT; LEG PAIN; LEG SWELLING; LUNG EMBOLISM; MEDICAL DECISION MAKING; MEDICAL DOCUMENTATION; MENOPAUSE; MENSTRUAL MIGRAINE; MENSTRUATION; OBESITY; ORAL CONTRACEPTION; OVARY CANCER; PATIENT ASSESSMENT; POSTMARKETING SURVEILLANCE; PREMENSTRUAL SYNDROME; PRESCRIPTION; PUBLIC HEALTH; RISK BENEFIT ANALYSIS; THROMBOPHILIA; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; UNPLANNED PREGNANCY; UNWANTED PREGNANCY; VENOUS THROMBOEMBOLISM; WEIGHT GAIN; CHEMICALLY INDUCED; CONSENSUS; CONSENSUS DEVELOPMENT; FEMALE; GERMANY; HEALTH; INTERNATIONAL COOPERATION; PUBLIC RELATIONS; RISK FACTOR; WOMEN'S HEALTH;

CONSENSUS; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; GERMANY; GLOBAL HEALTH; HUMANS; INTERNATIONALITY; INTERPROFESSIONAL RELATIONS; PROGESTERONE; RISK FACTORS; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH;

EID: 77954847213     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118910791749425     Document Type: Conference Paper

References (49)

1. Mills A. Combined oral contraception and the risk of venous thromboembolism. Hum Reprod 1997; 12: 2595-2598. (Pubitemid 28031714)
2. Goodyear-Smith A, Arroll B. Termination of pregnancy following panic-stopping of oral contraceptives. Contraception 2002; 66: 163-167. (Pubitemid 35217866)
3. Skjeldestad FE. Increased number of induced abortions in Norway after media coverage of adverse vascular events from the use of third-generation oral contraceptives. Contraception 1997; 55: 11-14. (Pubitemid 27036584)
4. Spitzer WO. The aftermath of a pill scare: regression to reassurance. Hum Reprod Update 1999; 5: 736-745.
5. Lewis MA, MacRae KD, Kuhl-Habichl D, Bruppacher R, Heinemann LA, Spitzer WO. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999; 14: 1493-1499. (Pubitemid 29265441)
6. Hennessy S, Berlin JA, Kinman JL, Margolis DJ, Marcus SM Strom BL. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis. Contraception 2001; 64: 125-133. (Pubitemid 33042599)
7. Dinger J. Oral contraceptives and venous thromboembolism: old questions revisited. J Fam Plann Reprod Health Care 2009; 35: 211-213.
8. Mackay J.XYZ & Others v Schering Health Care Limited, Organon Laboratories Limited, John Wyeth &Brother Limited. [2002] EWHC 1420(QB).
9. Spitzer WO. The 1995 pill scare revisited: anatomy of a non-epidemic. Hum Reprod 1997; 12: 2347-2357
10. Ciliska D, Thomas H, Buffett C. An Introduction to Evidence-Informed Public Health and a Compendium of Critical Appraisal Tools for Public Health Practice. February 2008. http://www.nccmt.ca/pubs/eiph-backgrounder.pdf [Accessed 27 May 2010].
11. American College of Obstetricians and Gynecologists (ACOG). Non-contraceptive Uses of Hormonal Contraception. ACOG Practice Guideline Number 110. January 2010. Obstet Gynecol 2010; 115: 206-218.
12. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism. A 25 year population based study. Arch Int Med 1998; 158: 585-593.
13. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-763.
14. Mohllajee AP, Curtis KM, Martins SL, Peterson HB. Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review. Contraception 2006; 73: 166-178.
15. Pomp ER, Rosendaal FR, Doggen CJM. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol 2008; 83: 97-102.
16. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S-400S.
17. Chandra D, Parisini E, Mozaffarian D. Meta-analysis: travel and risk for venous thromboembolism. Ann Intern Med 2009; 151: 180-190.
18. Pomp ER, le Cessie S, Rosendaal FR, Doggen CJR. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007; 139: 289-296.
19. Ros HS, Lichtenstein P, Belloco R, Petersson G, Cnattingius S. Increased risks of circulatory diseases in late pregnancy and puerperium. Epidemiology 2001; 12: 456-460. (Pubitemid 32566488)
20. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJM. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008; 6: 632-637.
21. Heinemann LAJ, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007; 75: 328-336.
22. Dinger JC, Heinemann LAJ, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observation. Contraception 2007; 75: 344-354. (Pubitemid 46551071)
23. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143: 697-706.
24. Ory HW. Mortality associated with fertility and fertility control: 1983. Fam Plann Perspect 1983; 15: 57-63.
25. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133: 32-37.
26. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339: b2890.
27. Severinsen MT, Kristensen SR, Overvad K, Dethlefsen C, Tjønneland A, Johnsen SP. Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with caution. J Clin Epidemiol 2010; 63: 223-228.
28. Gallo MF, Nanda K, Grimes DA, Schulz KF. Twenty micrograms vs. >20 microg estrogen oral contraceptives for contraception: systematic review of randomized controlled trials. Contraception 2005; 71: 162-169.
29. Culwell KR, Curtis KM. Use of contraceptive methods by women with current venous thrombosis on anticoagulant therapy: a systematic review. Contraception 2009; 80: 337-345.
30. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008; 336: 1227-1231. (Pubitemid 351809317)
31. Jick SS, Hagberg KW, Hernandez RK, Kaye JA. Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism. Contraception 2010; 81: 16-21.
32. De Lignieres B, Basdevant A, Thomas G, Thalabard JC, Mercier-Bodard C, Conard J, et al. Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 1986; 62: 536-541. (Pubitemid 16138173)
33. Kroon UB, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 1994; 71: 420-423. (Pubitemid 24100664)
34. Alhenc-Gelas M, Plu-Bureau G, Guillonneau S, Kirzin JM, Aiach M, Ochat N, et al. Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives. J Thromb Haemost 2004; 2: 1594-1600. (Pubitemid 40186176)
35. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125: 605-613.
36. Grimes DA, Schulz KF, Raymond EG. Surrogate end points in women's health research: science, protoscience and pseudoscience. Fertil Steril 2010; 93: 1731-1734.
37. Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heineman L. First time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56: 141-146. (Pubitemid 27450823)
38. Herings RM, Urquhart J, Leufkens HG. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999; 354: 127-128. (Pubitemid 29313151)
39. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000; 160: 49-52.
40. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et al.; for the WHI Investigators. Estrogen plus progestin and the risk of venous thrombosis. JAMA 2004; 292: 1573-1580.
41. Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007; 110: 587-593. (Pubitemid 47359582)
42. Eng PM, Seeger JD, Loughlin J, Clifford CR, Mentor S, Walker AM. Supplementary data collection with case-cohort analysis to address potential confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores. Pharmacoepidemiol Drug Saf 2008; 17: 297-305. (Pubitemid 351404040)
43. Van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJM, Rosendaal FR. Effects of oestrogen dose and progestogen type on venous thrombotic risk associated with oral contraceptives: results of the MEGA case-control study. BMJ 2009; 339: b2921.
44. Shapiro S, Dinger J. Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies. J Fam Plann Reprod Health Care 2010; 36: 33-38.
45. US Food and Drug Administration (FDA). FDA monograph on physician labelling for Yasmin 28 tablets (drospirenone and ethinyl estradiol). http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/021098s017lbl.pdf [Accessed 27 May 2010].
46. Lidegaard O. Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies (Letter). J Fam Plann Reprod Health Care 2010; 36: 103-104.
47. Shapiro S, Dinger J. Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies (Letter). J Fam Plann Reprod Health Care 2010; 36: 104-105.
48. Spitzer WO. Bias or causality: Interpreting recent evidence of oral contraceptive studies. Am J Obstet Gynecol 1998; 179: S43-S50.
49. Shapiro S. Causation, bias and confounding: a hitchhiker's guide to the epidemiological galaxy. Part 3: Principles of causality in epidemiological research: statistical stability, dose- and duration-response effects, internal and external consistency, analogy and biological plausibility. J Fam Plann Reprod Health Care 2008; 34: 261-264.